November 11, 2021 09:00 ET | Source: FemPulse
SAN FRANCISCO, November 11, 2021 — FemPulse Corporation, a private, clinical-stage bioelectronic medicine company, developing a novel wearable bioelectronic device for the personalized treatment of medical conditions in women, today announced the issuance of a European patent covering its vaginally-inserted nerve stimulation technology. FemPulse has previously been issued five US patents, two Chinese patents, and two Australian patents.
The European Patent Office has granted Patent EP 2858555 B1 to the Company. The issued patent, entitled “Devices and Methods for Stimulating Nerves”, spans 10 claims and provides similarly broad protection as the Company’s existing patents issued in other worldwide jurisdictions.
“It is very gratifying for me that the European Patent Office has joined the US, Chinese, and Australian patent offices in confirming the novelty of our wearable bioelectronic technology,” commented Dr. Alexandra Haessler, co-founder and Chief Medical Officer of FemPulse, who authored the patent. “Studies show that the prevalence of overactive bladder (OAB), the first application of our bioelectronic device platform, does not differ across populations, so that one in six women worldwide suffer from OAB. It has always been my goal to offer women everywhere a convenient and affordable solution, and IP protection in Europe, as well as the US, China, and Australia, will help make this possible. Surgically implanted neuromodulation is the gold standard for treating OAB, and our non-implanted, wearable neuromodulation device will hopefully provide the benefits of neuromodulation to orders of magnitude more women.”
“This European patent, and all of our other patents worldwide, cover our platform technology and are not limited to any single indication such as OAB,” added Peter Fredericks, Chairman of FemPulse. “Our wearable technology provides nerve stimulation in the upper vagina, based on Dr. Haessler’s insight that the nerves affecting numerous medical conditions including OAB coalesce there, and that this is also a unique anatomical location for a connected device to collect actionable body core data. We will be speaking with global distribution partners, for which worldwide IP protection for our wearable bioelectronic platform not limited to any indication is obviously important.”
About FemPulse Corporation
FemPulse Corporation is a privately held clinical-stage bioelectronic medicine company developing a novel wearable bioelectronic platform for the personalized treatment of medical conditions in women. FemPulse’s vaginally-inserted, wearable neuromodulation device is intended to provide mild electrical nerve stimulation as a first-line alternative to pharmaceutical medications. The device is designed to sense and collect data, with communication to a patient’s smartphone and physicians. The initial application is to treat the one in six women worldwide suffering from overactive bladder (OAB). For more information, visit www.fempulse.com.
Peter Fredericks, Chairman